Holen Sie sich die Stockscreener-App
14.28
5.62%
0.76
Handel nachbörslich:
14.28
Schlusskurs vom Vortag:
$13.52
Offen:
$13.65
24-Stunden-Volumen:
116.01K
Relative Volume:
0.79
Marktkapitalisierung:
$11.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.0537
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
+16.86%
1M Leistung:
+33.46%
6M Leistung:
+24.39%
1J Leistung:
-97.78%
1-Tages-Spanne:
$13.29
$15.90
1-Wochen-Bereich:
$13.00
$20.99
52-Wochen-Spanne:
$6.1478
$720.72
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Vergleichen Sie RNAZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
14.28 | 12.40M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
TransCode reports positive safety data from TTX-MC138 phase 1a trial By Investing.com - Investing.com South Africa
Transcode Therapeutics’ TTX-MC138 achieves safety endpoint in Phase 1a study - TipRanks
Transcode Therapeutics completes phase 1a trial with TTX-MC138 in metastatic disease at ESMOSEC filing - MarketScreener
TransCode Therapeutics, Inc. Completes Phase 1a Clinical Trial with TTX-MC138 - TradingView
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO - WV News
How to manage a losing position in TransCode Therapeutics Inc.July 2025 Rallies & Short-Term High Return Strategies - newser.com
Why TransCode Therapeutics Inc. stock is considered a top pick2025 Trading Recap & Risk Controlled Swing Alerts - newser.com
Is TransCode Therapeutics Inc. trending in predictive chart modelsJuly 2025 Decliners & Community Consensus Picks - newser.com
Exit strategy if you’re trapped in TransCode Therapeutics Inc.July 2025 Gainers & Real-Time Buy Zone Alerts - newser.com
Can TransCode Therapeutics Inc. stock weather global recession2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Is a relief rally coming for TransCode Therapeutics Inc. holdersJuly 2025 Reactions & Daily Profit Focused Screening - newser.com
Using Bollinger Bands to evaluate TransCode Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Does TransCode Therapeutics Inc. qualify in momentum factor screeningBuy Signal & Weekly Setup with ROI Potential - newser.com
Heatmap analysis for TransCode Therapeutics Inc. and competitors2025 Market Sentiment & Free Safe Capital Growth Stock Tips - newser.com
Is TransCode Therapeutics Inc. stock poised for growthEarnings Summary Report & Verified High Yield Trade Plans - newser.com
CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs - The Star
Is TransCode Therapeutics Inc. stock oversold or undervaluedMarket Growth Summary & AI Driven Stock Movement Reports - newser.com
Does TransCode Therapeutics Inc. fit your quant trading modelJuly 2025 WrapUp & Accurate Trade Setup Notifications - newser.com
CK Life Merges Polynoma with TransCode in $125M DealNews and Statistics - IndexBox
CK Life Sciences sees low geopolitical risks in a US merger - The Standard (HK)
Multi asset correlation models including TransCode Therapeutics Inc.July 2025 Highlights & Risk Managed Investment Strategies - newser.com
TransCode Therapeutics (NASDAQ:RNAZ) Earns “Sell (E+)” Rating from Weiss Ratings - Defense World
Critical Analysis: Century Therapeutics (NASDAQ:IPSC) and TransCode Therapeutics (NASDAQ:RNAZ) - Defense World
CKLIFE SCIENCES Estimates Completion of TransCode Preferred Stock Conversion in 6 Mths at Earliest - AASTOCKS.com
How hedge fund analytics apply to TransCode Therapeutics Inc. stockJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline - citybuzz
TransCode Therapeutics, Inc. (RNAZ) Stock :Soars as $25M Investment and Polynoma Acquisition Ignite Growth Prospects - parameter.io
TransCode Therapeutics To Acquire Polynoma; $25M Financing By a Subsidiary Of CK Life Sciences - citybiz
TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences - MarketScreener
TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout - Sahm
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
Transcode announces the acquisition of Polynoma and a $25 mln financing by subsidiary of CK Life Sciences - MarketScreener
TransCode Therapeutics stock soars after Polynoma acquisition By Investing.com - Investing.com Canada
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company - WV News
Transcode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Menafn.com
Chart based exit strategy for TransCode Therapeutics Inc.2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Strategies to average down on TransCode Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
TransCode Therapeutics Amends Patent License Agreement - TipRanks
TransCode Therapeutics (NASDAQ:RNAZ) Trading Down 1.5% – What’s Next? - Defense World
Will TransCode Therapeutics Inc. stock go up soonMarket Activity Report & Growth Oriented Trade Recommendations - newser.com
Is TransCode Therapeutics Inc. stock bottoming outJuly 2025 Big Picture & Real-Time Volume Analysis Alerts - newser.com
TransCode Therapeutics Passes Key Proposals at Annual Meeting - MSN
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):